View Future GrowthAligned Genetics 過去の業績過去 基準チェック /06Aligned Geneticsの収益は年間平均-3.1%の割合で減少していますが、 Life Sciences業界の収益は年間 減少しています。収益は年間3.1% 10%割合で 増加しています。 Aligned Geneticsの自己資本利益率は7.4%であり、純利益率は17.6%です。主要情報-3.14%収益成長率-7.24%EPS成長率Life Sciences 業界の成長53.72%収益成長率9.97%株主資本利益率7.39%ネット・マージン17.64%前回の決算情報31 Mar 2026最近の業績更新分析記事 • Apr 01Aligned Genetics' (KOSDAQ:238120) Problems Go Beyond Weak ProfitThe market wasn't impressed with the soft earnings from Aligned Genetics, Inc. ( KOSDAQ:238120 ) recently. Our analysis...Reported Earnings • Mar 14Full year 2024 earnings released: EPS: ₩287 (vs ₩450 in FY 2023)Full year 2024 results: EPS: ₩287. Revenue: ₩15.8b (up 3.7% from FY 2023). Net income: ₩4.13b (up 28% from FY 2023). Profit margin: 26% (up from 21% in FY 2023). The increase in margin was primarily driven by higher revenue.Reported Earnings • Mar 12Full year 2023 earnings released: EPS: ₩225 (vs ₩324 in FY 2022)Full year 2023 results: EPS: ₩225. Revenue: ₩15.2b (up 11% from FY 2022). Net income: ₩3.24b (up 39% from FY 2022). Profit margin: 21% (up from 17% in FY 2022). The increase in margin was driven by higher revenue.Reported Earnings • Mar 14Full year 2022 earnings released: EPS: ₩324 (vs ₩771 in FY 2021)Full year 2022 results: EPS: ₩324 (down from ₩771 in FY 2021). Revenue: ₩13.8b (up 17% from FY 2021). Net income: ₩2.33b (down 58% from FY 2021). Profit margin: 17% (down from 47% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.すべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Jul 01Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩3,565, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 17x in the Life Sciences industry in South Korea. Total loss to shareholders of 18% over the past three years.New Risk • Jun 01New major risk - Revenue and earnings growthEarnings have declined by 3.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 3.1% per year over the past 5 years. High level of non-cash earnings (37% accrual ratio). Minor Risk Market cap is less than US$100m (₩52.0b market cap, or US$34.5m).分析記事 • Apr 01Aligned Genetics' (KOSDAQ:238120) Problems Go Beyond Weak ProfitThe market wasn't impressed with the soft earnings from Aligned Genetics, Inc. ( KOSDAQ:238120 ) recently. Our analysis...New Risk • Apr 01New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 36% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (36% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Profit margins are more than 30% lower than last year (18% net profit margin). Market cap is less than US$100m (₩58.6b market cap, or US$38.9m).お知らせ • Mar 17Aligned Genetics, Inc., Annual General Meeting, Mar 31, 2026Aligned Genetics, Inc., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: seminar room, 599, gosan-ro, gyeonggi-do, gunpo South KoreaNew Risk • Feb 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩85.1b market cap, or US$59.5m).Valuation Update With 7 Day Price Move • Feb 25Investor sentiment improves as stock rises 44%After last week's 44% share price gain to ₩6,050, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 18x in the Life Sciences industry in South Korea. Total returns to shareholders of 40% over the past three years.分析記事 • Feb 05Aligned Genetics, Inc.'s (KOSDAQ:238120) Share Price Could Signal Some RiskWith a median price-to-earnings (or "P/E") ratio of close to 15x in Korea, you could be forgiven for feeling...Valuation Update With 7 Day Price Move • Feb 04Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩4,305, the stock trades at a trailing P/E ratio of 16.2x. Average trailing P/E is 16x in the Life Sciences industry in South Korea. Total returns to shareholders of 6.4% over the past three years.分析記事 • Nov 12These 4 Measures Indicate That Aligned Genetics (KOSDAQ:238120) Is Using Debt SafelySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Buy Or Sell Opportunity • Aug 05Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 12% to ₩3,475. The fair value is estimated to be ₩2,882, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.2% over the last 3 years. Earnings per share has declined by 5.5%.Buy Or Sell Opportunity • Jul 11Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 11% to ₩3,350. The fair value is estimated to be ₩2,786, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.2% over the last 3 years. Earnings per share has declined by 5.5%.Buy Or Sell Opportunity • Jun 11Now 24% overvalued after recent price riseOver the last 90 days, the stock has risen 14% to ₩3,460. The fair value is estimated to be ₩2,799, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.2% over the last 3 years. Earnings per share has declined by 5.5%.Reported Earnings • Mar 14Full year 2024 earnings released: EPS: ₩287 (vs ₩450 in FY 2023)Full year 2024 results: EPS: ₩287. Revenue: ₩15.8b (up 3.7% from FY 2023). Net income: ₩4.13b (up 28% from FY 2023). Profit margin: 26% (up from 21% in FY 2023). The increase in margin was primarily driven by higher revenue.お知らせ • Mar 12Aligned Genetics, Inc., Annual General Meeting, Mar 31, 2025Aligned Genetics, Inc., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 50, munwoncheonggye 2-gil, gyeonggi-do, gwacheon South Koreaお知らせ • Jan 21Aligned Genetics, Inc. (KOSDAQ:A238120) announces an Equity Buyback for KRW 1,000 million worth of its shares.Aligned Genetics, Inc. (KOSDAQ:A238120) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its common stock pursuant to a trust agreement with IBK SECURITIES CO., LTD. The purpose of the program is to enhance shareholder value and stabilizing stock prices. The program will expire on July 20, 2025. As of January 20, 2025, the company had no shares held in treasury within the dividend payable range acquisition and through Other Acquisition.Buy Or Sell Opportunity • Jan 08Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 5.3% to ₩3,185. The fair value is estimated to be ₩2,646, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.6% over the last 3 years. Earnings per share has declined by 27%.New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩44.7b market cap, or US$31.1m).Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩3,110, the stock trades at a trailing P/E ratio of 18x. Average trailing P/E is 13x in the Life Sciences industry in South Korea. Total loss to shareholders of 26% over the past three years.分析記事 • Nov 20Aligned Genetics, Inc.'s (KOSDAQ:238120) Shareholders Might Be Looking For ExitWith a price-to-earnings (or "P/E") ratio of 16x Aligned Genetics, Inc. ( KOSDAQ:238120 ) may be sending bearish...New Risk • Nov 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩53.0b market cap, or US$37.9m).Valuation Update With 7 Day Price Move • Nov 20Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ₩3,685, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 13x in the Life Sciences industry in South Korea. Total loss to shareholders of 14% over the past three years.New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩44.9b market cap, or US$34.1m).分析記事 • Aug 12Aligned Genetics, Inc.'s (KOSDAQ:238120) Business Is Yet to Catch Up With Its Share PriceAligned Genetics, Inc.'s ( KOSDAQ:238120 ) price-to-earnings (or "P/E") ratio of 14.9x might make it look like a sell...Reported Earnings • Mar 12Full year 2023 earnings released: EPS: ₩225 (vs ₩324 in FY 2022)Full year 2023 results: EPS: ₩225. Revenue: ₩15.2b (up 11% from FY 2022). Net income: ₩3.24b (up 39% from FY 2022). Profit margin: 21% (up from 17% in FY 2022). The increase in margin was driven by higher revenue.New Risk • Oct 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (16% net profit margin). Market cap is less than US$100m (₩67.2b market cap, or US$49.7m).Valuation Update With 7 Day Price Move • Oct 12Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩9,910, the stock trades at a trailing P/E ratio of 32.6x. Average trailing P/E is 36x in the Life Sciences industry in South Korea. Total loss to shareholders of 13% over the past three years.Reported Earnings • Mar 14Full year 2022 earnings released: EPS: ₩324 (vs ₩771 in FY 2021)Full year 2022 results: EPS: ₩324 (down from ₩771 in FY 2021). Revenue: ₩13.8b (up 17% from FY 2021). Net income: ₩2.33b (down 58% from FY 2021). Profit margin: 17% (down from 47% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • May 19Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩10,550, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 22x in the Life Sciences industry in South Korea. Total returns to shareholders of 51% over the past three years.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩10,300, the stock trades at a trailing P/E ratio of 13.4x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 47% over the past three years.Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improved over the past weekAfter last week's 25% share price gain to ₩9,600, the stock trades at a trailing P/E ratio of 17.4x. Average trailing P/E is 24x in the Life Sciences industry in South Korea. Total returns to shareholders of 42% over the past three years.Valuation Update With 7 Day Price Move • Aug 04Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩11,600, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 29x in the Life Sciences industry in South Korea. Total returns to shareholders of 57% over the past three years.分析記事 • Apr 06If You Like EPS Growth Then Check Out Aligned Genetics (KOSDAQ:238120) Before It's Too LateFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Is New 90 Day High Low • Feb 26New 90-day low: ₩7,370The company is down 29% from its price of ₩10,450 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 3.0% over the same period.分析記事 • Feb 11Update: Aligned Genetics (KOSDAQ:238120) Stock Gained 29% In The Last Three YearsWhile Aligned Genetics, Inc. ( KOSDAQ:238120 ) shareholders are probably generally happy, the stock hasn't had...Is New 90 Day High Low • Feb 08New 90-day low: ₩8,440The company is down 23% from its price of ₩11,000 on 10 November 2020. The South Korean market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 7.0% over the same period.お知らせ • Feb 02Aligned Genetics, Inc., Annual General Meeting, Mar 29, 2021Aligned Genetics, Inc., Annual General Meeting, Mar 29, 2021, at 09:00 Korea Standard Time.Is New 90 Day High Low • Jan 18New 90-day low: ₩8,980The company is down 15% from its price of ₩10,600 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 15% over the same period.Is New 90 Day High Low • Dec 22New 90-day low: ₩9,360The company is down 22% from its price of ₩12,000 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 14% over the same period.Is New 90 Day High Low • Oct 26New 90-day low: ₩9,940The company is down 3.0% from its price of ₩10,300 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 12% over the same period.収支内訳Aligned Genetics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSDAQ:A238120 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Mar 2615,7352,7756,4272,28531 Dec 2516,0162,9116,2602,01730 Sep 2517,3513,7436,1542,46530 Jun 2517,1733,3175,8672,37831 Mar 2516,5094,0555,6422,22531 Dec 2415,7784,1285,6162,29230 Sep 2414,9992,4785,3642,37330 Jun 2414,9333,3155,1942,06731 Mar 2414,9903,4425,1041,72231 Dec 2315,2153,2365,1251,68430 Sep 2314,2091,7754,8621,42730 Jun 2314,0722,1884,7961,35231 Mar 2313,7642,1134,5391,32731 Dec 2213,7532,3334,2751,07930 Sep 2213,8895,3464,44498630 Jun 2212,8494,1774,21999631 Mar 2212,9424,6114,03787731 Dec 2111,7625,5423,79494430 Sep 2110,3463,9683,37894930 Jun 2110,0593,3373,33186131 Mar 218,3221,8553,35692431 Dec 207,9574683,46681630 Sep 207,484-1093,50182530 Jun 207,3591023,93164431 Mar 207,7383753,69182031 Dec 197,7941173,62988530 Sep 197,486-2773,6531,02630 Jun 196,799-8643,4271,25231 Mar 196,425-1,0143,7621,08331 Dec 185,675-1,5883,8831,15630 Sep 185,385-2,0984,0491,03430 Jun 185,600-1,8014,0521,01731 Mar 185,630-1,8813,9591,20831 Dec 175,636-1,7544,00994030 Sep 175,487-1,2023,83080130 Jun 175,085-1,6893,86659331 Mar 174,806-1,5263,62646531 Dec 164,712-1,5563,39257830 Sep 164,407-1,3862,99260030 Jun 164,249-8332,52471531 Mar 164,150-7402,58861231 Dec 154,096-2612,341587質の高い収益: A238120 非現金収入 のレベルが高いです。利益率の向上: A238120の現在の純利益率 (17.6%)は、昨年(24.6%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A238120の収益は過去 5 年間で年間3.1%減少しました。成長の加速: A238120は過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: A238120は過去 1 年間で収益成長率がマイナス ( -31.6% ) となったため、 Life Sciences業界平均 ( -26.7% ) と比較することが困難です。株主資本利益率高いROE: A238120の 自己資本利益率 ( 7.4% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/31 12:19終値2026/07/31 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aligned Genetics, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
分析記事 • Apr 01Aligned Genetics' (KOSDAQ:238120) Problems Go Beyond Weak ProfitThe market wasn't impressed with the soft earnings from Aligned Genetics, Inc. ( KOSDAQ:238120 ) recently. Our analysis...
Reported Earnings • Mar 14Full year 2024 earnings released: EPS: ₩287 (vs ₩450 in FY 2023)Full year 2024 results: EPS: ₩287. Revenue: ₩15.8b (up 3.7% from FY 2023). Net income: ₩4.13b (up 28% from FY 2023). Profit margin: 26% (up from 21% in FY 2023). The increase in margin was primarily driven by higher revenue.
Reported Earnings • Mar 12Full year 2023 earnings released: EPS: ₩225 (vs ₩324 in FY 2022)Full year 2023 results: EPS: ₩225. Revenue: ₩15.2b (up 11% from FY 2022). Net income: ₩3.24b (up 39% from FY 2022). Profit margin: 21% (up from 17% in FY 2022). The increase in margin was driven by higher revenue.
Reported Earnings • Mar 14Full year 2022 earnings released: EPS: ₩324 (vs ₩771 in FY 2021)Full year 2022 results: EPS: ₩324 (down from ₩771 in FY 2021). Revenue: ₩13.8b (up 17% from FY 2021). Net income: ₩2.33b (down 58% from FY 2021). Profit margin: 17% (down from 47% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jul 01Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩3,565, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 17x in the Life Sciences industry in South Korea. Total loss to shareholders of 18% over the past three years.
New Risk • Jun 01New major risk - Revenue and earnings growthEarnings have declined by 3.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 3.1% per year over the past 5 years. High level of non-cash earnings (37% accrual ratio). Minor Risk Market cap is less than US$100m (₩52.0b market cap, or US$34.5m).
分析記事 • Apr 01Aligned Genetics' (KOSDAQ:238120) Problems Go Beyond Weak ProfitThe market wasn't impressed with the soft earnings from Aligned Genetics, Inc. ( KOSDAQ:238120 ) recently. Our analysis...
New Risk • Apr 01New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 36% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (36% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Profit margins are more than 30% lower than last year (18% net profit margin). Market cap is less than US$100m (₩58.6b market cap, or US$38.9m).
お知らせ • Mar 17Aligned Genetics, Inc., Annual General Meeting, Mar 31, 2026Aligned Genetics, Inc., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: seminar room, 599, gosan-ro, gyeonggi-do, gunpo South Korea
New Risk • Feb 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩85.1b market cap, or US$59.5m).
Valuation Update With 7 Day Price Move • Feb 25Investor sentiment improves as stock rises 44%After last week's 44% share price gain to ₩6,050, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 18x in the Life Sciences industry in South Korea. Total returns to shareholders of 40% over the past three years.
分析記事 • Feb 05Aligned Genetics, Inc.'s (KOSDAQ:238120) Share Price Could Signal Some RiskWith a median price-to-earnings (or "P/E") ratio of close to 15x in Korea, you could be forgiven for feeling...
Valuation Update With 7 Day Price Move • Feb 04Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩4,305, the stock trades at a trailing P/E ratio of 16.2x. Average trailing P/E is 16x in the Life Sciences industry in South Korea. Total returns to shareholders of 6.4% over the past three years.
分析記事 • Nov 12These 4 Measures Indicate That Aligned Genetics (KOSDAQ:238120) Is Using Debt SafelySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Buy Or Sell Opportunity • Aug 05Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 12% to ₩3,475. The fair value is estimated to be ₩2,882, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.2% over the last 3 years. Earnings per share has declined by 5.5%.
Buy Or Sell Opportunity • Jul 11Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 11% to ₩3,350. The fair value is estimated to be ₩2,786, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.2% over the last 3 years. Earnings per share has declined by 5.5%.
Buy Or Sell Opportunity • Jun 11Now 24% overvalued after recent price riseOver the last 90 days, the stock has risen 14% to ₩3,460. The fair value is estimated to be ₩2,799, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.2% over the last 3 years. Earnings per share has declined by 5.5%.
Reported Earnings • Mar 14Full year 2024 earnings released: EPS: ₩287 (vs ₩450 in FY 2023)Full year 2024 results: EPS: ₩287. Revenue: ₩15.8b (up 3.7% from FY 2023). Net income: ₩4.13b (up 28% from FY 2023). Profit margin: 26% (up from 21% in FY 2023). The increase in margin was primarily driven by higher revenue.
お知らせ • Mar 12Aligned Genetics, Inc., Annual General Meeting, Mar 31, 2025Aligned Genetics, Inc., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 50, munwoncheonggye 2-gil, gyeonggi-do, gwacheon South Korea
お知らせ • Jan 21Aligned Genetics, Inc. (KOSDAQ:A238120) announces an Equity Buyback for KRW 1,000 million worth of its shares.Aligned Genetics, Inc. (KOSDAQ:A238120) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its common stock pursuant to a trust agreement with IBK SECURITIES CO., LTD. The purpose of the program is to enhance shareholder value and stabilizing stock prices. The program will expire on July 20, 2025. As of January 20, 2025, the company had no shares held in treasury within the dividend payable range acquisition and through Other Acquisition.
Buy Or Sell Opportunity • Jan 08Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 5.3% to ₩3,185. The fair value is estimated to be ₩2,646, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.6% over the last 3 years. Earnings per share has declined by 27%.
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩44.7b market cap, or US$31.1m).
Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩3,110, the stock trades at a trailing P/E ratio of 18x. Average trailing P/E is 13x in the Life Sciences industry in South Korea. Total loss to shareholders of 26% over the past three years.
分析記事 • Nov 20Aligned Genetics, Inc.'s (KOSDAQ:238120) Shareholders Might Be Looking For ExitWith a price-to-earnings (or "P/E") ratio of 16x Aligned Genetics, Inc. ( KOSDAQ:238120 ) may be sending bearish...
New Risk • Nov 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩53.0b market cap, or US$37.9m).
Valuation Update With 7 Day Price Move • Nov 20Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ₩3,685, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 13x in the Life Sciences industry in South Korea. Total loss to shareholders of 14% over the past three years.
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩44.9b market cap, or US$34.1m).
分析記事 • Aug 12Aligned Genetics, Inc.'s (KOSDAQ:238120) Business Is Yet to Catch Up With Its Share PriceAligned Genetics, Inc.'s ( KOSDAQ:238120 ) price-to-earnings (or "P/E") ratio of 14.9x might make it look like a sell...
Reported Earnings • Mar 12Full year 2023 earnings released: EPS: ₩225 (vs ₩324 in FY 2022)Full year 2023 results: EPS: ₩225. Revenue: ₩15.2b (up 11% from FY 2022). Net income: ₩3.24b (up 39% from FY 2022). Profit margin: 21% (up from 17% in FY 2022). The increase in margin was driven by higher revenue.
New Risk • Oct 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (16% net profit margin). Market cap is less than US$100m (₩67.2b market cap, or US$49.7m).
Valuation Update With 7 Day Price Move • Oct 12Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩9,910, the stock trades at a trailing P/E ratio of 32.6x. Average trailing P/E is 36x in the Life Sciences industry in South Korea. Total loss to shareholders of 13% over the past three years.
Reported Earnings • Mar 14Full year 2022 earnings released: EPS: ₩324 (vs ₩771 in FY 2021)Full year 2022 results: EPS: ₩324 (down from ₩771 in FY 2021). Revenue: ₩13.8b (up 17% from FY 2021). Net income: ₩2.33b (down 58% from FY 2021). Profit margin: 17% (down from 47% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • May 19Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩10,550, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 22x in the Life Sciences industry in South Korea. Total returns to shareholders of 51% over the past three years.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩10,300, the stock trades at a trailing P/E ratio of 13.4x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 47% over the past three years.
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improved over the past weekAfter last week's 25% share price gain to ₩9,600, the stock trades at a trailing P/E ratio of 17.4x. Average trailing P/E is 24x in the Life Sciences industry in South Korea. Total returns to shareholders of 42% over the past three years.
Valuation Update With 7 Day Price Move • Aug 04Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩11,600, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 29x in the Life Sciences industry in South Korea. Total returns to shareholders of 57% over the past three years.
分析記事 • Apr 06If You Like EPS Growth Then Check Out Aligned Genetics (KOSDAQ:238120) Before It's Too LateFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Is New 90 Day High Low • Feb 26New 90-day low: ₩7,370The company is down 29% from its price of ₩10,450 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 3.0% over the same period.
分析記事 • Feb 11Update: Aligned Genetics (KOSDAQ:238120) Stock Gained 29% In The Last Three YearsWhile Aligned Genetics, Inc. ( KOSDAQ:238120 ) shareholders are probably generally happy, the stock hasn't had...
Is New 90 Day High Low • Feb 08New 90-day low: ₩8,440The company is down 23% from its price of ₩11,000 on 10 November 2020. The South Korean market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 7.0% over the same period.
お知らせ • Feb 02Aligned Genetics, Inc., Annual General Meeting, Mar 29, 2021Aligned Genetics, Inc., Annual General Meeting, Mar 29, 2021, at 09:00 Korea Standard Time.
Is New 90 Day High Low • Jan 18New 90-day low: ₩8,980The company is down 15% from its price of ₩10,600 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 15% over the same period.
Is New 90 Day High Low • Dec 22New 90-day low: ₩9,360The company is down 22% from its price of ₩12,000 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 14% over the same period.
Is New 90 Day High Low • Oct 26New 90-day low: ₩9,940The company is down 3.0% from its price of ₩10,300 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 12% over the same period.